Clinical Trial Update: Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating CP-751,871 in combination with Sunitinib for patients with advanced cancer/solid tumors was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CP-751,871 (dalotuzumab)
• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Advanced Cancer, Advanced Solid Tumors | Phase 1 | Status: TERMINATED | Results posted: 2014-06-09